Recent research on chimeric antigen receptor T cells in children with refractory/relapsed acute lymphoblastic leukemia.
10.7499/j.issn.1008-8830.2210056
- Author:
Nan WEI
1
;
Tian-Ping CHEN
1
Author Information
1. Department of Hematology, Anhui Provincial Children's Hospital, Hefei 230051, China.
- Publication Type:Journal Article
- Keywords:
Acute lymphoblastic leukemia;
Child;
Chimeric antigen receptor T cell;
Immunotherapy
- MeSH:
Humans;
Child;
Receptors, Chimeric Antigen;
Immunotherapy;
China;
Hematopoietic Stem Cell Transplantation;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy*
- From:
Chinese Journal of Contemporary Pediatrics
2023;25(2):210-216
- CountryChina
- Language:Chinese
-
Abstract:
At present, the treatment of refractory/relapsed acute lymphoblastic leukemia is still in a difficult situation, and even if the intensity of chemotherapy is increased or it is combined with hematopoietic stem cell transplantation, some children may have a poor prognosis and a short survival time. Chimeric antigen receptor T-cell (CAR-T) immunotherapy uses genetically engineered T cells and does not rely on the human leukocyte antigen pathway to recognize tumor-specific antigens, and then CAR-T cells bind to target antigen cells to trigger immune response, thereby exerting a sustained anti-leukemia effect. As the most rapidly developed tumor immunotherapy, major breakthroughs have been made for CAR-T cells in the treatment of various hematological tumors, but there still lacks a comprehensive system for the research, development, and production of CAR-T cells and standardized diagnosis and treatment protocols in China. This article reviews the recent research on CAR-T cells in children with refractory/relapsed acute lymphoblastic leukemia.
